SUTRO BIOPHARMA, INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
SUTRO BIOPHARMA, INC. (STRO) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2023-03-30
- SUTRO BIOPHARMA, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
- SUTRO BIOPHARMA, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2021 was $0.00.
- SUTRO BIOPHARMA, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2020 was $0.00.
- SUTRO BIOPHARMA, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2019 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-30 |
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-18 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-16 |
| 2018-12-31 | $0.00 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |